0
Business
Pharma Q4 outlook mixed: Hospitals steady, generics face revlimid drag
May 4, 2026
Scroll
Posted 3 hours ago by
Indian pharma and healthcare firms face a mixed March quarter. While hospitals anticipate steady growth, generic drugmakers grapple with lost Revlimid sales and pricing challenges. Lupin and Divi's are poised for strong performance, with Sun Pharma and Torrent showing resilience. Apollo Hospitals expects robust traction across its diverse segments.
Economic Times
Coverage and analysis from India. All insights are generated by our AI narrative analysis engine.
India
Bias: center
People's Voices (0)
Leave a comment
0/500
Note: Comments are moderated. Please keep it civil. Max 3 comments per day.